-Thalassemia: HiJAKing Ineffective Erythropoiesis and Iron Overload
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
-thalassemia encompasses a group of monogenic diseases that have in common defective synthesis of -globin. The defects involved are extremely heterogeneous and give rise to a large phenotypic spectrum, with patients that are almost asymptomatic to cases in which regular blood transfusions are required to sustain life. As a result of the inefficient synthesis of -globin, the patients suffer from chronic anemia due to a process called ineffective erythropoiesis (IE). The sequelae of IE lead to extramedullary hematopoiesis (EMH) with massive splenomegaly and dramatic iron overload, which in turn is responsible for many of the secondary pathologies observed in thalassemic patients. The processes are intimately linked such that an ideal therapeutic approach should address all of the complications. Although -thalassemia is one of the first monogenic diseases to be described and represents a global health problem, only recently has the scientific community started to focus on the real molecular mechanisms that underlie this disease, opening new and exciting therapeutic perspectives for thalassemic patients worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“In 2005, five different research teams [26–30] described an activating mutation (V617F) in the pseudokinase domain of Jak2 that is associated with ≥90% of cases of polycythemia vera and ∼50% of cases of essential thrombocythemia and chronic idiopathic myelofibrosis.”
Hepcidin, a urinary antimicrobial peptide synthesized in the liver
Park, C. H., Valore, E. V., Waring, A. J., & Ganz, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008922200 · Cited by 2,168 · cited 1×
“The absence of FoxO3 was associated with reduction in erythrocyte lifespan as well as an enhanced mitotic arrest in intermediate erythroid progenitor cells, resulting in a decreased rate of erythroid maturation.”
Hentze, M. W., Muckenthaler, M. U., & Andrews, N. C. (2004) · Cell · doi:10.1016/s0092-8674(04)00343-5 · Cited by 1,736 · cited 1×
“This process is tightly regulated by an array of events that include cytokine signaling and cell-cell interactions, mainly in the context of erythroblastic islands, a specialized niche for the maturation of erythroid progenitors [15].”
Pigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., & Loréal, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008923200 · Cited by 1,697 · cited 1×
“In 2005, five different research teams [26–30] described an activating mutation (V617F) in the pseudokinase domain of Jak2 that is associated with ≥90% of cases of polycythemia vera and ∼50% of cases of essential thrombocythemia and chronic idiopathic myelofibrosis.”
Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter
Donovan, A., Brownlie, A., Zhou, Y., Shepard, J., Pratt, S. J., Moynihan, J., Paw, B. H., Drejer, A., Barut, B., Zapata, A., et al. (2000) · Nature · doi:10.1038/35001596 · Cited by 1,667
McKie, A. T., Marciani, P., Rolfs, A., Brennan, K., Wehr, K., Barrow, D., Miret, S., Bomford, A., Peters, T. J., Farzaneh, F., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80425-6 · Cited by 1,422 · cited 1×
“Some examples include growth hormone, prolactin, TPO, GM-CSF, interleukin 3, and interleukin 5.”
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., & Ganz, T. (2003) · Blood · doi:10.1182/blood-2002-10-3235 · Cited by 1,417 · cited 1×
“In 2005, five different research teams [26–30] described an activating mutation (V617F) in the pseudokinase domain of Jak2 that is associated with ≥90% of cases of polycythemia vera and ∼50% of cases of essential thrombocythemia and chronic idiopathic myelofibrosis.”
LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity
Krause, A., Neitz, S., Mägert, H.-J., Schulz, A., Forssmann, W.-G., Schulz-Knappe, P., & Adermann, K. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01920-7 · Cited by 1,324 · cited 1×
“The absence of FoxO3 was associated with reduction in erythrocyte lifespan as well as an enhanced mitotic arrest in intermediate erythroid progenitor cells, resulting in a decreased rate of erythroid maturation.”
A Novel Mammalian Iron-regulated Protein Involved in Intracellular Iron Metabolism
Abboud, S., & Haile, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000713200 · Cited by 1,267
Interleukin-6 induces hepcidin expression through STAT3
Wrighting, D. M., & Andrews, N. C. (2006) · Blood · doi:10.1182/blood-2006-06-027631 · Cited by 983 · cited 1×
“In 2005, five different research teams [26–30] described an activating mutation (V617F) in the pseudokinase domain of Jak2 that is associated with ≥90% of cases of polycythemia vera and ∼50% of cases of essential thrombocythemia and chronic idiopathic myelofibrosis.”
High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin
Tanno, T., Bhanu, N. V., Oneal, P. A., Goh, S.-H., Staker, P., Lee, Y. T., Moroney, J. W., Reed, C. H., Luban, N. L., Wang, R.-H., et al. (2007) · Nature Medicine · doi:10.1038/nm1629 · Cited by 854 · cited 2×
“Since high levels of ID1 have been found to inhibit cell differentiation, its up-regulation due to a sustained activation of Jak2 by EPO in β-thalassemia could explain the less mature erythroid progenitors observed.”
Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)
Peyssonnaux, C., Zinkernagel, A. S., Schuepbach, R. A., Rankin, E., Vaulont, S., Haase, V. H., Nizet, V., & Johnson, R. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31370 · Cited by 639 · cited 1×
“In 2005, five different research teams [26–30] described an activating mutation (V617F) in the pseudokinase domain of Jak2 that is associated with ≥90% of cases of polycythemia vera and ∼50% of cases of essential thrombocythemia and chronic idiopathic myelofibrosis.”
Suppression of hepcidin during anemia requires erythropoietic activity
Pak, M., Lopez, M. A., Gabayan, V., Ganz, T., & Rivera, S. (2006) · Blood · doi:10.1182/blood-2006-06-028787 · Cited by 472 · cited 1×
“In 2005, five different research teams [26–30] described an activating mutation (V617F) in the pseudokinase domain of Jak2 that is associated with ≥90% of cases of polycythemia vera and ∼50% of cases of essential thrombocythemia and chronic idiopathic myelofibrosis.”
Hepcidin in iron overload disorders
Papanikolaou, G., Tzilianos, M., Christakis, J. I., Bogdanos, D., Tsimirika, K., MacFarlane, J., Goldberg, Y. P., Sakellaropoulos, N., Ganz, T., & Nemeth, E. (2005) · Blood · doi:10.1182/blood-2004-12-4844 · Cited by 445 · cited 1×
“…one of the first monogenic diseases to be described and represents a global health problem, only recently has the scientific community started to focus on the real molecular mechanisms that underlie this disease, opening new and exciting therapeutic perspectives for thalassemic patients worldwide.”
The Molecular Mechanism of Hepcidin-mediated Ferroportin Down-Regulation
De Domenico, I., Ward, D. M., Langelier, C., Vaughn, M. B., Nemeth, E., Sundquist, W. I., Ganz, T., Musci, G., & Kaplan, J. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-01-0060 · Cited by 434
Tanno, T., Porayette, P., Sripichai, O., Noh, S.-J., Byrnes, C., Bhupatiraju, A., Lee, Y. T., Goodnough, J. B., Harandi, O., Ganz, T., et al. (2009) · Blood · doi:10.1182/blood-2008-12-195503 · Cited by 352
Comparative studies of duodenal and macrophage ferroportin proteins
Canonne-Hergaux, F., Donovan, A., Delaby, C., Wang, H.-J., & Gros, P. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00227.2005 · Cited by 124
Decreased hepcidin mRNA expression in thalassemic mice
Adamsky, K., Weizer, O., Amariglio, N., Breda, L., Harmelin, A., Rivella, S., Rachmilewitz, E., & Rechavi, G. (2004) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04734.x · Cited by 108 · cited 1×
“…one of the first monogenic diseases to be described and represents a global health problem, only recently has the scientific community started to focus on the real molecular mechanisms that underlie this disease, opening new and exciting therapeutic perspectives for thalassemic patients worldwide.”
Self-citationRamirez, J., Schaad, O., Durual, S., Cossali, D., Docquier, M., Beris, P., Descombes, P., & Matthes, T. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07441.x · Cited by 96 · cited 1×
“2.2.”
InfluentialWeizer‐Stern, O., Adamsky, K., Amariglio, N., Levin, C., Koren, A., Breuer, W., Rachmilewitz, E., Breda, L., Rivella, S., Ioav Cabantchik, Z., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06258.x · Cited by 80
Self-citationWeizer-Stern, O., Adamsky, K., Amariglio, N., Rachmilewitz, E., Breda, L., Rivella, S., & Rechavi, G. (2006) · American Journal of Hematology · doi:10.1002/ajh.20549 · Cited by 71 · cited 1×
“…one of the first monogenic diseases to be described and represents a global health problem, only recently has the scientific community started to focus on the real molecular mechanisms that underlie this disease, opening new and exciting therapeutic perspectives for thalassemic patients worldwide.”
Self-citation
Cited by
Non-transfusion-dependent thalassemias
Musallam, K. M., Rivella, S., Vichinsky, E., & Rachmilewitz, E. A. (2013) · Haematologica · doi:10.3324/haematol.2012.066845 · Cited by 326
Self-citationMacrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia
Ramos, P., Casu, C., Gardenghi, S., Breda, L., Crielaard, B. J., Guy, E., Marongiu, M. F., Gupta, R., Levine, R. L., Abdel-Wahab, O., et al. (2013) · Nature Medicine · doi:10.1038/nm.3126 · Cited by 227
Self-citationGinzburg, Y., & Rivella, S. (2011) · Blood · doi:10.1182/blood-2011-03-283614 · Cited by 201
Self-citationMinihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera
Casu, C., Oikonomidou, P. R., Chen, H., Nandi, V., Ginzburg, Y., Prasad, P., Fleming, R. E., Shah, Y. M., Valore, E. V., Nemeth, E., et al. (2016) · Blood · doi:10.1182/blood-2015-10-676742 · Cited by 148
Piga, A., Perrotta, S., Gamberini, M. R., Voskaridou, E., Melpignano, A., Filosa, A., Caruso, V., Pietrangelo, A., Longo, F., Tartaglione, I., et al. (2019) · Blood · doi:10.1182/blood-2018-10-879247 · Cited by 119
Metadata
- Authors
- Melchiori, L., Gardenghi, S., & Rivella, S.
- Venue
- Advances in Hematology
- Publisher
- Wiley
- Published
- 2010
- Volume
- 2010
- Pages
- 1-7
- ISSN
- 1687-9104 (ISSN-L)
- 1687-9112
- OpenAlex
- W2083874255
- Cited by
- 74
- References
- 22
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.